http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 24 Jun 2024 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Press+Releases/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html <p> SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent member of its Board of Directors. </p><p> Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical http://www.streetinsider.com/Business+Wire/Contineum+Therapeutics+Announces+Appointment+of+Sarah+Boyce+to+Board+of+Directors/23389996.html Mon, 24 Jun 2024 16:05:00 -0400 A.08978371 A.12659897 A.40462110 AKCA BLI CTNM IONS NOVN NVS O.00134870 O.00170057 O.00222301 O.00222506 O.04996291 O.15127974 O.36764426 RNA